Dapagliflozin Cuts Cardiovascular Events in Patients With Heart Failure, T2D
WEDNESDAY, Dec. 27, 2023 -- For patients with heart failure and type 2 diabetes (T2D), dapagliflozin does not reduce urinary albumin-to-creatinine ratio (UACR) but does reduce some cardiovascular events, according to a study published online Nov. 27...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Heart | Heart Failure | Pharmaceuticals | Study